Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
August 2, 2025
Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor α, in monkeys
Shawn Fernando, Yuji Mano
Studies in Health Technology and Informatics
|
October 4, 2007
Speech recognition in dental software systems: features and functionality
Jeannie Yuhaniak Irwin, Shawn Fernando, Titus Schleyer, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
August 13, 2008
Quality assessment of English and Spanish oral cancer websites
Jeannie Yuhaniak Irwin, Teena Wali, Shawn Fernando, et al.
European Journal of Immunology
|
August 26, 2018
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding
J Bradford Kline, Shawn Fernando, Erin N Ross, et al.
Brain Research
|
July 14, 2009
Regulation of protein kinase C isozymes during early postnatal hippocampal development
Sudarshana Purkayastha, Suraj Shawn Fernando, Souleymane Diallo, et al.
Brain Research
|
April 17, 2009
Curcumin blocks brain tumor formation
Sudarshana Purkayastha, Alexandra Berliner, Suraj Shawn Fernando, et al.
Journal of Neurochemistry
|
February 21, 2007
Plasticity of 5-HT 1A receptor-mediated signaling during early postnatal brain development
Mukti Mehta, Zagloul Ahmed, Suraj Shawn Fernando, et al.
Cancer Biology & Therapy
|
April 14, 2018
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
Nicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, et al.
Cancer Science
|
March 23, 2021
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models
Keiji Furuuchi, Katherine Rybinski, James Fulmer, et al.
Oncotarget
|
September 9, 2017
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
James Bradford Kline, Rina P Kennedy, Earl Albone, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Journal of Pharmaceutical and Biomedical Analysis
|
August 2, 2025
Comprehensive assessments of pharmacokinetics and immunogenicity of farletuzumab ecteribulin, a novel antibody-drug conjugate against tumors expressing folate receptor α, in monkeys
Shawn Fernando, Yuji Mano
Studies in Health Technology and Informatics
|
October 4, 2007
Speech recognition in dental software systems: features and functionality
Jeannie Yuhaniak Irwin, Shawn Fernando, Titus Schleyer, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
August 13, 2008
Quality assessment of English and Spanish oral cancer websites
Jeannie Yuhaniak Irwin, Teena Wali, Shawn Fernando, et al.
European Journal of Immunology
|
August 26, 2018
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding
J Bradford Kline, Shawn Fernando, Erin N Ross, et al.
Brain Research
|
July 14, 2009
Regulation of protein kinase C isozymes during early postnatal hippocampal development
Sudarshana Purkayastha, Suraj Shawn Fernando, Souleymane Diallo, et al.
Brain Research
|
April 17, 2009
Curcumin blocks brain tumor formation
Sudarshana Purkayastha, Alexandra Berliner, Suraj Shawn Fernando, et al.
Journal of Neurochemistry
|
February 21, 2007
Plasticity of 5-HT 1A receptor-mediated signaling during early postnatal brain development
Mukti Mehta, Zagloul Ahmed, Suraj Shawn Fernando, et al.
Cancer Biology & Therapy
|
April 14, 2018
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
Nicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, et al.
Cancer Science
|
March 23, 2021
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models
Keiji Furuuchi, Katherine Rybinski, James Fulmer, et al.
Oncotarget
|
September 9, 2017
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
James Bradford Kline, Rina P Kennedy, Earl Albone, et al.
Page
of 2